Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03703856 · ClinicalTrials.gov registry record · Phase 4

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

A Phase 4 study of Alzheimer Disease, sponsored by University of California, San Diego.

Active
Registry status
Phase 4
Development phase
53
Enrollment target
1
Study location

NCT03703856 is a Phase 4 study of Alzheimer Disease that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 53 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03703856, a Phase 4 study of Alzheimer Disease, is active but no longer recruiting, sponsored by University of California, San Diego.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
53 participants
Enrollment target
1
Study location

Study Summary

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Memantine

Study Locations (1)

California

  • Clinical Teaching Facility (CTF-B102) at UCSD Medical Center - San Diego

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2019-01-31
Est. Completion 2025-12-30
Phase Phase 4

Sponsor

University of California, San Diego

775 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03703856

The ClinicalTrials.gov registry entry for NCT03703856 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.

NCT03703856 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03703856 about?

NCT03703856 is a clinical study titled "Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease". The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

What is the current status of trial NCT03703856?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2019-01-31. Estimated completion is 2025-12-30.

What conditions does trial NCT03703856 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT03703856?

The interventions under investigation include: Memantine (DRUG).

Who is sponsoring clinical trial NCT03703856?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03703856 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.